NWBO Adds Another 3 Trials to Pipeline

Mid-Range AI Valuation of These New Trials Increases The Value More Than The Current Market Capitalization

A few months ago, I produced a valuation of Northwest Biotherapeutics (NWBO) using AI. With Tuesday’s release of the Q3 10-Q I found it necessary to revise this model for the following reasons:

• Announcement of an expansion of the refractory Phase 2 refractory melanoma trial at Roswell Park to include refractory bladder, breast and lung cancer. These th…